title: Phase II evaluation of the sulfonylurea LY186,641 in men with hormone independent metastatic prostate cancer.
authors.affiliation: Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison.
authors.forename: G
authors.initials: G
authors.lastname: Wilding
authors.forename: G
authors.initials: G
authors.lastname: Grindey
authors.forename: N
authors.initials: N
authors.lastname: Munshi
authors.forename: D
authors.initials: D
authors.lastname: Seitz
authors.forename: L
authors.initials: L
authors.lastname: Einhorn
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012983:Soft Tissue Neoplasms / Q000556:secondary; D013453:Sulfonylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D013453:Sulfonylurea Compounds; C058179:sulofenur